Zepbound coverage cut

CVS Caremark is dropping Zepbound from several standard formularies, forcing some patients to switch weight-loss drugs by July 1, 2025. (business.caremark.com) CVS Caremark said Zepbound will no longer be included in its Standard Control, Advanced Control, and Value formularies, and said it will continue to prefer “similar medications, including Wegovy.” InsuranceNewsNet reported that beneficiaries were notified of the change and began planning medication switches. (business.caremark.com) (insurancenewsnet.com) One patient in the InsuranceNewsNet report, Meghan Lena, said she plans to move to Novo Nordisk’s Wegovy rather than lose covered access to treatment. The article described the switch as a response to insurance rules, not to a new medical problem or a new trial result. (insurancenewsnet.com) These drugs are used for chronic weight management, not short-term dieting. Zepbound is tirzepatide, a once-weekly injection approved for adults with obesity, or overweight adults with at least one weight-related condition, alongside diet and exercise. (lilly.com) (accessdata.fda.gov) Wegovy is semaglutide, another once-weekly obesity drug in the same broad class of gut-hormone medicines. Novo Nordisk said in February 2026 that it cut the U.S. list price of Wegovy, and in March 2026 it launched a subscription program for the drug. (accessdata.fda.gov) (novonordisk-us.com 1) (novonordisk-us.com 2) CVS Caremark framed the Zepbound exclusion as a pricing decision. The company said its formulary strategy uses negotiated discounts and preferred products to deliver “low net cost” for employer and health-plan clients. (business.caremark.com 1) (business.caremark.com 2) That leaves many patients navigating coverage rules set by pharmacy benefit managers, the companies that decide which drugs sit on preferred insurance lists. InsuranceNewsNet and other recent reports have documented similar cutbacks or tighter limits by insurers facing high spending on obesity medicines. (insurancenewsnet.com 1) (insurancenewsnet.com 2) (insurancenewsnet.com 3) Eli Lilly has tried to soften the blow for some commercially insured patients outside government programs. Lilly’s savings page says eligible patients whose insurance does not cover Zepbound can pay starting at $299 for a one-month prescription, though terms and exclusions apply. (lilly.com) For patients who built treatment plans around Zepbound, the immediate question is no longer which drug their doctor started first. It is which drug their insurance card will still cover after July 1. (business.caremark.com) (insurancenewsnet.com)